ERAS Erasca, Inc.
Legal ·
Erasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action.
Erasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025.
Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company says these alterations account for more than five million new cancer patients diagnosed globally each year. Its modality-agnostic pipeline pursues three strategies: targeting upstream and downstream MAPK pathway nodes, targeting RAS directly, and targeting escape routes that enable resistance. Its lead program, ERAS-0015, is a pan-RAS molecular glue licensed from Guangzhou Joyo Pharmatech, being tested in the AURORAS-1 Phase 1 trial, which the FDA cleared in May 2025, and in a Phase 1 trial in China sponsored by Joyo. In a January 2026 update, Erasca reported ongoing confirmed and unconfirmed responses, no dose-limiting toxicities and linear pharmacokinetics, and it had dosed patients at 40 mg once daily after a low dose of 8 mg once daily. Its second clinical program, ERAS-4001, is a potential first-in-class pan-KRAS inhibitor, and ERAS-12, an EGFR D2/D3 biparatopic antibody, is at discovery stage.
| Product or program | What it is | Stage |
|---|---|---|
| ERAS-0015 | Pan-RAS molecular glue for RAS-mutated solid tumors | Phase 1 |
| ERAS-4001 | Potential first-in-class pan-KRAS inhibitor for KRAS-mutated solid tumors | clinical-stage |
| ERAS-12 | EGFR D2/D3 biparatopic antibody | discovery stage |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $92.9 million | $115.4 million |
| Net income (loss) | -$124.5 million | -$161.7 million |
| Cash from operations | -$95.5 million | -$109.4 million |
| Cash and equivalents | $73.8 million | $67.7 million |
| Short-term investments | $202.3 million | $230.6 million |
Our latest story on this, dated Aug 11, 2026: "Erasca faces securities class action and ERAS-0015 derivative suit". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 13, 2026: "Erasca launches $500,000,000 stock offering, then prices 31,428,572 shares at $17.50". The story links the filing or release it is based on. Read the story.
Erasca, Inc. trades under the ticker ERAS on NASDAQ.
Erasca, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Erasca, Inc. is 1761918. Its filings are on SEC EDGAR.
349,762,035 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Erasca, Inc. under United States.
Our directory classifies Erasca, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Erasca, Inc. is US29479A1088.
aibio.space lists Erasca, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company says these alterations account for more than five million new cancer patients diagnosed globally each year.
ERAS-0015: Pan-RAS molecular glue for RAS-mutated solid tumors Stage: Phase 1.
ERAS-4001: Potential first-in-class pan-KRAS inhibitor for KRAS-mutated solid tumors Stage: clinical-stage.
Erasca, Inc. reported a net loss of $124.5 million for the fiscal year ended Dec 31, 2025, and used $95.5 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio